Japan-based companies Daiichi Sankyo, Astellas Pharma and Mitsubishi Tanabe Pharma have collaborated to jointly carry out a programme to discover new therapeutic drugs using drug-repositioning compound libraries.

Known as Joint Open Innovation of Drug Repositioning (JOINUS), the programme will be conducted as a part of the open innovation activities of the three companies.

Originally, drug repositioning is a concept of reutilisation of medicines and is intended to identify indications different from the initially targeted one.

Several compounds, including marketed drugs and those for which development has been stopped, are evaluated in drug repositioning.

However, the JOINUS programme has been designed to develop new drugs from compounds that were not marketed.

As part of the programme, the collaborators have generated library containing compounds, for which development has been stopped after implementation of clinical or preclinical studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Known as Joint Open Innovation of Drug Repositioning (JOINUS), the programme will be conducted as a part of the open innovation activities of the three companies.”

The companies will offer the library as a drug-repositioning compound library to Japanese research institutions accepted to the programme for evaluation through their respective in vitro assays.

The new library will contain compounds whose pharmacological activities have been demonstrated and basic safety profiles have been confirmed.

If a compound contained in the library is found to have a beneficial pharmacological activity in a new assay, it is expected to enter clinical trials in a shorter period of time compared with general drug discovery approaches.

Through the use of the generated drug-repositioning compound library, the three companies aim to increase the possibility of discovering new therapeutic drugs by facilitating open innovation with research institutions in Japan.